MAIA Biotechnology, Inc.
10-K
March 23, 2026
Key Highlights
- Ateganosine's Phase 2 trial (THIO-101) shows impressive efficacy, significantly ...
- FDA Fast Track Designation for Ateganosine in NSCLC and multiple Orphan Drug Des...
- Robust intellectual property portfolio with numerous issued and pending patents,...
Read Analysis
🤖 AI Generated